Posters
The effects of three nonsteroidal anti-inflammatory drugs on operative mydriasis maintaining and postoperative inflammation
Poster Details
First Author: T.Sarenac Vulovic SERBIA
Co Author(s): S. Sreckovic N. Petrovic M. Janicijevic Petrovic K. Janicijevic D. Todorovic S. Jovanovic
Abstract Details
Purpose:
The aim of this study was to compare the effects of tree non-steroidal anti-inflammatory drugs (Indomethacyn, Diclofenac andd Nepavenac) compared to sterod therapy in patients underwent cataracts urgery.
Setting:
Clinic of ophthalmology, Clinical Centre Kragujevac, Kragujevac, SerbiaFaculty of Medical sciences, Department of ophthalmology, University of Kragujevac, Serbia
Methods:
Our study included 100 patients referred to cataract surgery, taking into account excluding criteria. All partients were divided in four groupps (n=25): Igroup-pre/postoperative Intomethacyn 0.1%; II group-pre/postoperative Diclofenac 0.1%; III group- pre/postoperative Nepavenac 0.1%; and IV group-postoperative steroid single. During our examination, we measured: intraoperative pupil diameter changes, postoperative anterior chamber inflammation.
Results:
Our results indicated that intraoperative mydriasis maintaing was better in groups with preoperative using of non steroid anti-inflammatory drugs compared with patients with single steroid postoperatively, with statistical significance (p<0.05). There was no statistical significance differences between the groups using non steroidal anti-inflammatory drugs (p>0.05). Also, postoperative inflammation was statistically significant less in patients with pre/postoperatively used non steroid antiinflammatory drugs compared with steroid only postroperatively used patients (p<0.05), measured in appropriate intervals. There was no statistical singnificant differences between the first three examined groups.
Conclusions:
: Non steroidal antiinflammatory drugs used pre/postoperatively can maintain the mydriasis during cataract surgery; and thay reduce postoperatively inflammation in anterior chamber.
Financial Disclosure:
NONE
